written on 04.03.2014
Tags:
,

NICE R&D cost request sets orphan drug precedent with Soliris guidance

TAGS: ,

One way in which it differs, laid out in the HST interim process and methods statement, is that NICE will take into account what could be considered a "reasonable cost" for the medicine. NICE's methods statement specifically says this will be considered…

Latest Report